Data gathered: November 27
AI Stock Analysis - ARS Pharmaceuticals (SPRY)
Analysis generated March 31, 2024. Powered by Chat GPT.
ARS Pharmaceuticals is a healthcare company that focuses on developing therapies to improve outcomes for patients. They are primarily involved in the pharmaceutical sector where they work on innovative treatments. The company's mission is rooted in enhancing patient care and providing solutions for serious medical conditions. As a relatively young and dynamic firm, they are likely making strides in research and development, which could yield proprietary products that may serve untapped markets or offer superior alternatives to existing medications. The details of ARS Pharma’s product pipeline, market cap, and revenues would provide deeper insights into the company, but these details are not included in the prompt.
Stock Alerts - ARS Pharmaceuticals (SPRY)
 |
ARS Pharmaceuticals | November 22 Insider Alert: Tanimoto Sarina is selling shares |
|
ARS Pharmaceuticals | November 14 Price is up by 5.5% in the last 24h. |
|
ARS Pharmaceuticals | November 14 Insider Alert: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) is selling shares |
|
ARS Pharmaceuticals | November 13 Price is down by -5.8% in the last 24h. |
Alternative Data for ARS Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 92 | Sign up | Sign up | Sign up |
| Google Trends | 3 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,884 | Sign up | Sign up | Sign up |
| Twitter Followers | 464 | Sign up | Sign up | Sign up |
| Twitter Mentions | 25 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 66 | Sign up | Sign up | Sign up |
| Linkedin Employees | 128 | Sign up | Sign up | Sign up |
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.
| Price | $14.53 |
| Target Price | Sign up |
| Volume | 533,370 |
| Market Cap | $1.33B |
| Year Range | $7.65 - $17.49 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
ARS Pharmaceuticals: Demand Curve Is Key UnknownNovember 19 - SeekingAlpha |
 |
Research Analysts Set Expectations for SPRY FY2024 EarningsNovember 18 - ETF Daily News |
|
William Blair Has Bullish Forecast for SPRY FY2024 EarningsNovember 17 - ETF Daily News |
|
William Blair Issues Optimistic Forecast for SPRY EarningsNovember 16 - ETF Daily News |
|
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder Sells $9,533,346.24 in StockNovember 16 - ETF Daily News |
 |
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-TermNovember 14 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 2.1M | 19M | -17M | -19M | -22M | -0.200 |
| Q2 '24 | 500,000 | 110,000 | 390,000 | -13M | -15M | -0.130 |
| Q1 '24 | 0 | 93,000 | -93,000 | -10M | -13M | -0.110 |
| Q4 '23 | 0 | -40M | 40M | -7.2M | -10M | -0.070 |
| Q3 '23 | 0 | 15M | -15M | -15M | -18M | -0.160 |
Insider Transactions View All
| Tanimoto Sarina filed to sell 1,198,499 shares at $13.9. November 21 '24 |
| Lowenthal Richard E filed to sell 1,198,499 shares at $13.9. November 21 '24 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) filed to sell 5,266,883 shares at $17.2. November 13 '24 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) filed to sell 5,266,881 shares at $17.2. November 13 '24 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) filed to sell 5,257,328 shares at $17.8. November 13 '24 |
Similar companies
Read more about ARS Pharmaceuticals (SPRY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of ARS Pharmaceuticals?
The Market Cap of ARS Pharmaceuticals is $1.33B.
What is the current stock price of ARS Pharmaceuticals?
Currently, the price of one share of ARS Pharmaceuticals stock is $14.53.
How can I analyze the SPRY stock price chart for investment decisions?
The SPRY stock price chart above provides a comprehensive visual representation of ARS Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ARS Pharmaceuticals shares. Our platform offers an up-to-date SPRY stock price chart, along with technical data analysis and alternative data insights.
Does SPRY offer dividends to its shareholders?
As of our latest update, ARS Pharmaceuticals (SPRY) does not offer dividends to its shareholders. Investors interested in ARS Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of ARS Pharmaceuticals?
Some of the similar stocks of ARS Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.